InSilico Medicine is a globally leading generative AI-driven biotech company in terms of AIDD pipeline progress providing end-to-end solutions. Founded in 2014 at the Emerging Technology Centers of Johns Hopkins University in Baltimore, Maryland, the company has a global presence in the U.S., Greater China, Canada, and the Middle East.

By leveraging the company’s rapidly evolving, proprietary Pharma.AI platform across biology, chemistry and clinical development, the company aims at a mission to accelerate drug discovery and development. Pharma.AI platform consisting of Biology42, Chemistry42 and Medicine42, which are designed to be integrated across the drug discovery and development process to efficiently identify novel drug targets, design de novo molecules against both novel and known targets and optimize clinical development.